ZOLEDRONIC ACID, A LONG-ACTING BISPHOSPHONATE, FOR CHRONIC LOW BACK PAIN DUE TO MODIC CHANGES: A RANDOMIZED CONTROLLED TRIAL

Trial Profile

ZOLEDRONIC ACID, A LONG-ACTING BISPHOSPHONATE, FOR CHRONIC LOW BACK PAIN DUE TO MODIC CHANGES: A RANDOMIZED CONTROLLED TRIAL

Planning
Phase of Trial: Phase III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Acronyms ZAMOD
  • Sponsors Axsome Therapeutics
  • Most Recent Events

    • 09 May 2017 According to an Axsome media release, the start of this trial is planned following readouts from ongoing Phase 3 trials in CRPS and TRD (see profile 258879 and 266743 respectively)
    • 07 Mar 2017 According to an Axsome Therapeutics media release, in Feb 2017 company received IND clearance from the FDA to proceed this trial. The IND clearance builds upon previously reported positive results from the randomized, double-blind, placebo-controlled Phase 2 trial conducted with intravenous zoledronic acid showing a statistically significant reduction in low back pain intensity and NSAID usage as compared to placebo in patients with CLBP and MCs.
    • 24 Mar 2016 According to an Axsome Therapeutics media release, this trial is expected to initiate in the fourth quarter of 2016 or the first quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top